The Molecular Biology Unit (UBM), belonging to the Clinical Analysis Service of the Hospital Universitari y Politècnic La Fe de València, is a pioneering laboratory in the molecular diagnosis of cancer that serves both this hospital and different centers in the national territory. and that has a history of more than 25 years in the molecular diagnosis of cancer.
In this sense, Begoña Laiz, director of the Biomedical Diagnosis Area and head of the Clinical Analysis Service of La Fe, highlighted that “the healthcare activity carried out by this unit has experienced a striking increase in recent years, with more than 20,000 determinations being carried out. during the year 2020 and thereby showing clear leadership among public health services institutions “.
In general, the molecular studies carried out by this unit make it possible to establish personalized strategies in each patient, improving the diagnosis, establishing the individual risk or prognosis, predicting the response to treatment and / or monitoring the response to it.
Molecular Biology renews its ISO accreditation
Recently, this unit has renewed its UNE-EN ISO 15.189 accreditation obtained in 2018, granted by the National Accreditation Entity (ENAC) for molecular studies aimed at offering personalized medicine in cancer patients.
The implementation of this standard in 2018 positioned this unit as the clinical laboratory with the broadest scope and the largest volume of activity at the national level for carrying out molecular studies in cancer using cutting-edge technologies.
With the reaccreditation of 2020, it also expands the scope of its file for the second time, incorporating new molecular markers (such as genes of moderate penetrance in patients with hereditary breast or ovarian cancer syndrome), new methodologies (such as digital PCR) or faster and more robust molecular procedures. This second extension is the result of constant scientific and technological updating, and contributes to improving clinical care.
Marta Llop, Head of Quality for this unit, has indicated that “after the audit carried out, ENAC has concluded that this Unit has an effective quality management system, that the laboratory is technically competent and that the new methods implemented comply with with the norm, thus consolidating its commitment to quality and technical competence in healthcare activity “.
Its care work is mainly focused on three lines of work, (Hereditary predisposition to breast and ovarian cancer, Oncohematology and Therapeutic targets in solid tumors) offering a portfolio of services with more than 50 molecular markers that help in clinical management of the patient.
Inmaculada de Juan, Eva Barragán and Sarai Palanca, physicians responsible for the three lines of work, have ensured that “the unit is firmly committed to the needs required by precision medicine, ensuring excellence, effectiveness and quality in healthcare “.
–
